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Abstract
Previous studies have shown that elevated basal homocysteine levels are correlated among family members of 
patients with coronary vascular disease and juvenile venous thrombosis. This suggests the possibility of the presence 
of inherited basal mild hyperhomocysteinemia (mHH). We studied homocysteine levels, fasting as well as after 
methionine load, among 96 family members of 21 post-load hyperhomocysteinemic vascular index patients, i.e. 6 
parents, 27 offspring, 38 siblings, 19 uncles and aunts and 6 cousins. In 15 out of 21 screened families post-load ml-IH
was esti in at least one family member. Fa:>ting and post-load mHH was observed in 19 out of 89 (21%) 
screened family members (fasting homocysteine levels not measured in seven family members), and 31 out of 96 
screened family members (32%), respectively. In 40% of all family members, post-load mHH was not accompanied by
fasting mHH. conclude that both fasting and post-load mHH seems to be inherited in the majority of 
ic vascular patients.
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1. Introduction
Mild hyperhomocysteinemia (mHH), a risk fac-
tor lor premature i is detected in a
frequency of 9 47% in patients with premature
al or coronary stenotic arterial
[1-11]. In the
cerebral, 
disease or with
* Corresponding author, Tel: +  31 24 361 4545; lax: +31
24 354
general population mHH is present in up to 8% 
[1,2]. mHH can be caused by enzymatic defects 
such as heterozygosity for cystathionine synthase 
(CS) deficiency, or homozygosity for thermolabile 
5-methylenetetrahydrofolate reductase (MTHFR) 
deficiency, indicating a genetic cause in at least a 
subset of the detected patients [3,4,12-15]. Envi­
ronmental influences such as vitamin B12 and folic 
acid deficiency, and renal or liver disease can also 
induce mHH [1,16,17].
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Homocysteine blood concentrations were found 
to be correlated in monozygotic and dizygotic 
healthy twins [18,19] and were strongly correlated 
among family members of patients with coronary 
vascular disease [20-22]. These studies in family 
members of arterial occlusive diseased patients 
were performed on the base of fasting homocys­
teine concentration measurements only. Falcon et
value < 6.5 mmol/1), in the index patient of 
family 13 (7.7 mmol/1), hypertriglyceridemia was 
detected in the index patient of family 8 (5.46 
mmol/1; reference value <  2.00 mmol/1), and 
diabetes in the index patient of family 3 (fasting 
glucose: 9.4 mmol/1; reference value > 7.8 mmol/ 
1). All other index patients and family members 
had vitamin B6, vitamin B]2, folic acid, glucose,
al. [8] reported high plasma homocysteine levels in 
5 out of 8 families of patients with juvenile venous 
thrombosis.
In the present study, we have performed me­
thionine loading tests in 96 family members of 21 
hyperhomocysteinemic vascular patients. In these 
patients as well as their family members vitamin 
deficiencies or liver or renal failure which could 
lead to secondary mHH had been excluded. The 
prevalence of mHH, fasting as well as after me­
thionine loading, among the family members was 
assessed to examine the possibility of the presence 
of an inherited cause of mHH in the vascular
cholesterol, triglycerides levels within the normal 
ranges, were without liver or renal disease or 
hypertension of non-renovascular origin. From all 
patients and the family members information of 
intake of vitamin supplements and medical his­
tory was obtained. None of the 21 families and 
the studied parents were related to one other 
within the second generation.
2.2. Index vascular patients
Of the 21 hyperhomocysteinemic index patients 
with documented vascular disease, 10 patients had
patients. suffered from cerebral occlusive arterial disease, 3 
from peripheral occlusive arterial disease (2 inter-
2. Materials and methods
mittent claudication, and 1 subclavian arterial 
occlusion), 2 from anterior spinal arterial syn-
2.1. Methionine loading test and determination of  
hyperhomocysteinemia
drome, 2 from coronary occlusive arterial disease, 
3 from venous thrombosis (1 deep crural throm­
bosis and 2 cerebral thrombosis), and 1
In 21 vascular disease patients hyperhomocys­
teinemia was established on the basis of their 
homocysteine level after methionine loading ex­
ceeding the mean + 2  S.D.s post-load homocys­
teine level in 95 controls. Methionine loading tests 
(0.1 g L-methionine/kg body weight) were per-
members according to aformed in
protocol reported previously [23]. Plasma samples 
in the fasting state and 6 h after methionine load
concomitant coronary occlusive arterial disease 
and deep crural thrombosis. One family (Fig. I, 
family number 13) was also known with inherited 
protein C-deficiency [25]. The vascular disease 
became symptomatic in the index patients be­
tween their 16th and 50th year of age (38 +  8 
years; mean ±  S.D.), the mean age ±  S.D. at 
their screening was 39 ±  7 years.
2.3. Family members
were collected and centrifuged instantly. The total 
homocysteine concentration (free plus protein- 
bound) was measured by high-performance liquid
The methionine loading tests in the studied 
family members were performed on their own
chromatography (HPLC) [24]. At the time of request after detection of the index patient, except
screening, the index patient of family 10, his for 2 families (Fig. 1, family number 10 and 13)
parents and sibships, and one cousin (fasting and which were asked to volunteer in the screening of
post-load homocysteine levels of 11 and 46 /¿mol/ 
1, respectively) presented with decreased vitamin 
B,2 levels. Hypercholesterolemia was detected in 
the mother of family 4 (8.3 mmol/1; reference
mHH. The index patients of these 2 families were 
exceptionally young, i.e. 16 years of age at the 
time of their vascular incident. Only those families 
have been included in this study, in whom at least
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Fig. 1. (a and b) Twenty-one family pedigrees of vascular patients with post-load mild hyperhomocysteinemia. At the left side of  
the symbols, the total homocysteine concentration before (above) and after (below) methionine loading are shown. CVD indicates 
cerebral vascular disease; PAD, peripheral arterial disease; MI, myocardial infarction; VT, venous thrombosis; ASAS, anterior spinal 
artery syndrome; CRAO, central retinal artery occlusion; CRVO, central retinal venous occlusion; and Neo, neoplasm.
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and 43 female); i.e. 6 parents, 27 offspring and 39 
siblings. In family number 10 and 13 (Fig. 1) 10 
uncles and 9 aunts were also tested. These second 
degree family members were siblings of the fathers 
of both index cases in whom post-load mHH was 
revealed. In family number 10 another 6 third 
degree relatives (offspring of a post-load hyperho­
mocysteinemic second degree 
were screened with the methionine loading test. 
At the time of screening the mean age +  S.D. of 
the 97 family members was 33 + 9 years (range 
12-68 years). One sister used 
ments and was excluded from the study (Fig. 1, 
family number 7). Four family members suffered 
from vascular complications at the time of screen­
ing (Fig. 1, family number 4, 7, 13, 15). Their age 
at onset of vascular complications ranged from 37 
to 59 years of age (mean +  S.D. 44 + 8 years).
2.4. Control subjects
Because of previously observed differences in 
mean fasting and post-load homocysteine levels
between male, pre-menopausal and post-
menopausal female control subjects the studied 
index patients and family members were catego­
rized accordingly [3,26]. The fasting and post-load 
homocysteine concentration (2.5-97.5 percentile) 
respectively was in control men 8-18 and 25-54
/miol/1 (n 23), in control pre-menopausal
women 6-15 and 18-51 /¿mo I/I (n 46) and in
control post-menopausal women 6-19 and 25-69
/¿mol/1 (n 26) [27].
out of 19 screened second degree and 3 out of 7
screened third degree members revealed
post-load mHH. By definition, the post-load ho­
mocysteine concentrations of vascular index pa­
tients, and post-load 
family members were significantly higher than in 
controls (Table 1). Also the total group of studied
xi sign
than controls. Plasma folic acid concentrations 
vascular index patients, family members as one 
group and as subgroups with and without post­
load hyperhomocysteinemia, were statistically sig-
lower compared to 
vitamin B6 was 
hyperhomocysteinemic family members (Table 1).
Plasma 
in post-load
There was no evident sex difference among the 
hyperhomocysteinemic family members (17 of the 
42 male, and 14 of the 54 female family members;
X2 P  >  0.05).
3.2. Fasting mild 
and Table 1)
2/?,
Fasting mHH was present in 19 out of 89 
family members (21%), including 17 among 29 
post-load hyperhomocysteinemic family members, 
and 2 among 60 post-load normohomocysteine-
(fasting homocysteine levels 
not measured in 7 family members). Thus, in 
included family members, in 40%) post-load hyper­
homocysteinemia was not accompanied by fasting 
elevated levels.
Fasting were within
3. Results
3.1. Post- 
2a, and Table 1)
rner yxtememia (Fig.
normal range in 6 out of 20 index patients 
family number 3, 4, 17, 18, 19, 20; fasting homo-
, Incysteine level not measured in 1 index p<
5 out of the 6 families of these 6 patients, one 
more post-load
member was detected, and also in all
In 15 out of the 21 screened families post-load 
mHH was established in at least one family mem­
ber. In 31 out of 96 screened family 
post-load mHH was observed (32%). Post-load 
mHH was detected in 50%) of the parents (3 out of
6 parents), of the (7 out of 27
children) and in 29% of the siblings (11 out of 38 
siblings among 16 index vascular patients). Seven
$c fasting
m
' * \ L' tX
1
was within the normal range. In the 14 families, in 
whom
only 17 out of 24 posl-load
h y pe rh o m ocy steinemic family 
also elevated fasti
ïre su
cally significantly higher in
fl M in
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homocysteine concentrations above 54 /tmol/l in men, 51 /jmol/1 in premenopausal women and 69 /miol/1 in posi-menopausal 
women are defined as hyperhomocysteinemia.
post-load hyperhomocysteinemic family members, 
but also, albeit less strongly significantly, in post­
load normohomocysteinemic family members 
compared to the control group (Table 1).
4. Discussion
3.3. Vascular complications in family members
Four screened family members were known 
with vascular manifestations at the time of the 
methionine loading test. Three of them revealed 
post-load mHH (Fig. 1, family number 4, 7 and 
13). The fourth vascular affected family member 
(Fig. 1, family number 15) showed a high but 
normal post-load homocysteine concentration
In the present study, 71% of the families of a 
patient with various forms of arteriosclerosis had 
at least one other family member with post-load 
mHH. In 6 out of the 21 studied families no other 
relative had post-load mHH, but only 15 of the 40 
first degree relatives were studied, and therefore,
co uld
have been missed. Mildly elevated homocysteine 
levels were present in family members in 21% on 
the base of fasting and in 32% on the base
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FA 9.3 m |tpM M 2.3 11.3 ± 3.44 9.3 l n L 2.04 12.3 » sin 3.5 (n If II 4^ 14.4 !ÍU|«I 4.6
(n f  III»« 20)4
»6 52 ±
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The family members are divided into 31 family members with post-load mild 
normal post-load homocysteine concentration,
FA, plasma folic acid; B6, blood vitamin B6; BI2, blood vitamin B ,a.
The age is given in years; M, male; F, female.
'<  0.05; z < 0.01; 3<  0.0001; 4< 0.00001 (Wilcoxon rank sum H^-test).
ia, and 65 family members with
post-load homocysteine concentration. Our obser­
vations are in line with previous reports in which 
basal homocysteine concentration in healthy twins 
and in families of coronary vascular patients is 
reported to show a significant correlation [18-22]. 
The present study demonstrates that both fasting 
and post-load mHH, in the absence of vitamin 
deficiencies and renal or liver insufficiencies, 
seems to be inherited in the majority of vascular 
patients. Further enzymatic and molecular studies 
are needed to reveal the involved genetic enzy­
matic defects and their inheritance patterns. Re­
duced activities in the range of obligate carriers 
for CS-deficiency have been reported in hyperho- 
mocysteinemic vascular patients [3,4]. This finding 
was difficult to reconcile with the conclusion by 
Mudd et al. of a normal incidence of heart attacks
vascular [15,30]. Moreover, in the
Netherlands where the 833 T C transition is
detectable as the mutation in the gene on
chromosome 21 in 50% of alleles of homozygotes 
for CS-deficiency, in 60 cardiovascular pati
this mutation not be identified in
them [30]. The same holds true for the
tion in Ireland 
the CS
the 919 G “+ A mutation in
in 70% of
could not be in a group
of 100 Irish patients with
. From all these enzymatic and molecular
ss summarizing, it can 
that there is no evidence, so far, that
ity for deficiency plays a role as the basis of
mHH in vascular patients. In a previous study, we
an incidence of a thermolabile MTHFR
o r in a large group of obligate
erozygotes for CS-deficiency studied by question­
naires [28]. Furthermore, even in populations with 
the highest prevalence of homozygous CS-defi­
ciency, such as in Ireland, the calculated number 
of carriers is too low to account for the number of 
observed hyperhomocysteinemic vascular patients 
[29]. Indeed, very recently, it was reported that the 
finding of lowered CS-activity was not repro­
ducible in 96% of studied hyperhomocysteinemic
: car
is c
enzyme m
vascular patients [15 
sistently associated with the 677 C 
in the MTHFR gene on chromosome 1 [12], and 
a subject has to be homozygous for such mutation
► I I1
to produce
a
MTHFR
patients and 
lively [30],
[13,14].
s, i.e. 28% i 5%,
of this defect does not 
seem sufficient to provide on its own the base of
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all familial occurrence of mHH as observed in the 
present study.
It is still questionable whether, either fasting or 
post-load homocysteine concentration, is the most 
sensitive indicator of abnormal homocysteine 
metabolism. Both fasting and post-load mHH are 
considered risk factors for cardiovascular disease 
[1,5,32]. In case we screened for mHH only on the 
basis of fasting homocysteine levels, no more than 
14 out of 20 index patients (70%) and 17 out of 29
members with post-load mHH (59%) 
would have been considered hyperhomocysteine- 
mic. Even if family members of only the 14 index 
patients with fasting mHH had been screened for 
fasting homocysteine levels alone, 29% (7 out of 
24) of the family members who indeed showed 
post-load mHH, would have been classified as 
normohomocysteinemic. Post-load elevated ho­
mocysteine levels in the absence of fasting hyper- 
homocysteinemia is probably on the basis of 
another enzymatic defect than concomitant fast­
ing and post-load hyperhomocysteinemia [33]. In 
our present study, we have screened family mem­
bers of vascular index patients with post-load 
elevated homocysteine levels, in whom only in 
70% also abnormal fasting levels were present. 
None of the 21 index patients were known with 
fasting elevated and post-load normal homocys­
teine concentrations. Therefore, a selection in 
families has been made on the basis of this inclu­
sion criterion. However, studies on fasting homo­
cysteine levels in healthy twins and also in families 
of cardiovascular patients have been performed 
already previously, showing a strong correlation 
[18-22]. We prefer to perform both fasting and 
post-load homocysteine concentrations in vascu­
lar patients and family members to investigate 
their individual homocysteine status more com­
pletely [11,25,34-37].
Plasma folic acid concentrations, were signifi-
mic family members lower folic acid compared to 
controls, could be an indication of a common 
habit of low folate intake in these families, leading 
to hyperhomocysteinemia in some of the mem­
bers. However, in family members with hyperho­
mocysteinemia, the decrease in folic acid 
concentration was much more pronounced than 
in their normohomocysteinemic family members, 
comparable with the highly significantly lower 
levels in the vascular patients in these families. 
This is much more suggestive of the presence of a 
hereditary defect in homocysteine metabolism 
leading to a higher demand for folate in the 
hyperhomocysteinemic patients and their hyper- 
homocysteinemic family members.
Among the 96 investigated family members, 4 
had known vascular disease. Three of them were 
hyperhomocysteinemic, and one had high-normal 
post-load homocysteine concentration. Therefore, 
screening for mHH of family members suffering 
from vascular events among families of a hyper­
homocysteinemic patient, is recommended. About 
90% of the family members with post-load mHH 
revealed no subjective signs of vascular disease, at 
least so far. Most screened family members were 
younger than their respective index case. This
suggests that familial mild hyperhomocysteinemia
i
leading to symptomatic vascular disease has a low 
expression, may be age dependent and that homo­
cysteine in mild excess may require more trigger­
ing factors.
mHH in vascular patients can be normalized by 
vitamin B6 and/or folic acid treatment [11,25,34- 
37]. In case homocysteine-lowering intervention in 
hyperhomocysteinemic vascular patients and their 
hyperhomocysteinemic family members is clini­
cally beneficial in terms of preventing recurrent 
and first occurrence of arterial disease, respec­
tively, such treatment will be of significant impor­
tance in general health care.
cantly lower in vascular index patients, in family
members as one group, and in the subgroups of 
post-load normo- and hyperhomocysteinemic
Acknowledgements
family members, compared to controls. This find­
ing is in accordance with earlier observations of 
reduced, though not deficient, folic acid blood 
levels in cardiovascular patients [4,10,11]. Estab­
lishing both in normo- and hyperhomocysteine-
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